Image

Global Adrenal Corticosteroid Inhibitors Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Jan 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Jan 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Adrenal Corticosteroid Inhibitors Market, By Type (Breast Cancer, Prostate Cancer, Cushing's Syndrome, Others), Drug (Osilodrostat, Metyrapone, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Adrenal Corticosteroid Inhibitors Market

Adrenal Corticosteroid Inhibitors Market Analysis and Size

The adrenal corticosteroid inhibitors market is anticipated to witness huge growth during the forecast period. Rise in incidence of prostate cancer is boosting the adrenal corticosteroid inhibitor drugs market. As per the World Cancer Research Fund International records, in 2012, above 1.1 million cases of prostate cancer were witnessed, accounting for around 15% of cases in men anad nearly 8% of total new cases. It is also driven by increase in occurrence of breast cancer and high diagnostics rate.

Data Bridge Market Research analyses a growth rate in the adrenal corticosteroid inhibitors market in the forecast period 2023-2030. The expected CAGR of adrenal corticosteroid inhibitors market is tend to be around 12.5% in the mentioned forecast period. The market was valued at USD 2.25 billion in 2022, and it would grow upto USD 5.77 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Adrenal Corticosteroid Inhibitors Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (Breast Cancer, Prostate Cancer, Cushing's Syndrome, Others), Drug (Osilodrostat, Metyrapone, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

ChemGenix (India), Ciba AG (Switzerland), Crinetics Pharmaceuticals, Inc. (U.S.), HRA Pharma (U.S.), Merck KGaA (Germany), Novartis AG (U.S.), Recordati S.P.A (Italy), and Tocris Bioscience (U.K.)

Market Opportunities

  • Rising Incidence of Prostate Cancer
  • Increasing Demand for Retail Pharmacies

Market Definition

Adrenal corticosteroid inhibitors are the type which are extensively used for the treatment of cushing's syndrome and some types of solid tumors such as breast cancer. It employs their effect by hindering endogenous synthesis of hormones secreted by the adrenal cortex by interfering with the enzymes responsible for steroid synthesis pathway. These drugs are also used when the adrenal cortex is overactive and not leading towards cancer.

Adrenal Corticosteroid Inhibitors Market Dynamics

Drivers

  • Increasing Incidence of Breast Cancer

The increasing cases of breast cancer globally in developed and under-developed countries boosts the market. According to WHO, 58% of deaths caused by breast cancer mostly occur in under-developed or developing countries globally. In the year 2020, there were around 2.3 million women diagnosed with breast cancer and 685 000 deaths worldwide. As of the end of 2020, there were nearly 7.8 million women alive who were diagnosed with breast cancer in the past 5 years. Thus, this increasing prevalence boosts the demand for these inhibitors.

  • Increasing Demand for Oral Drugs

The increasing demand for oral drugs is anticipated to boost the market growth. The segment is projected to increase the global market as most of the products are available in capsule and tablet form and it is a very convenient route of administration.

Opportunities

  • Increasing Incidence of Prostate Cancer

According to World Cancer Research Fund International, around 1.1 million cases of prostate cancer were observed in 2012 which resulted for around 15% cases in men. In addition to this, growing prevalence of Cushing’s syndrome boosts the demand for these drugs. The estimated numbers of new cancer cases and deaths in 2022. In the year 2022, there will be approximately 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the U.S. Thus, this increasing prevalence boosts the market growth.

  • Growing Demand for Retail Pharmacies

Increase in the number of cortical necrosis therapeutics being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global adrenal corticosteroid market during the forecast period.

  • High Cost of Treatment

The increasing expenditure related with medications hamper the market growth. These inhibitors cost high and people in underdeveloped countries, result in the under treatment of several patients. This hampers the market growth.

This adrenal corticosteroid inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the adrenal corticosteroid inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Adrenal Corticosteroid Inhibitors Market         

COVID-19 has left a major impact that has disturbed every business, and its long-term consequences are anticipated to influence industry growth during the forecast period 2023-2030. Shift of healthcare infrastructure towards managing COVID-19 has led to drug approval cancellations and delays in clinical trials.

However, in the post-pandemic era, the biotechnology and pharmaceutical industries are anticipated to witness a huge growth in the future, because of the demand for vaccine and other treatment drugs for COVID-19. Therefore, the market is seeing a rise in the current era.

Global Adrenal Corticosteroid Inhibitors Market Scope

The adrenal corticosteroid inhibitors market is segmented on the basis of drug, type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Breast Cancer
  • Prostate Cancer
  • Cushing's Syndrome
  • Others

Drug

  • Osilodrostat
  • Metyrapone
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Adrenal Corticosteroid Inhibitors Market Regional Analysis/Insights

The adrenal corticosteroid inhibitors market is analyzed and market size insights and trends are provided by drug, type, distribution channel and end-user as referenced above.

The major countries covered in the adrenal corticosteroid inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for adrenal corticosteroid inhibitors market throughout the forecasted period due to the high demand of diseases specific treatment and increased patient awareness level as well as high prevalence of breast cancer and Cushing’s disease.

Asia-Pacific dominates the market due to the rise in number of generic manufacturers in this region as well as increasing disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Adrenal Corticosteroid Inhibitors Market Share Analysis

The adrenal corticosteroid inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to adrenal corticosteroid inhibitors market.

Key players operating in the adrenal corticosteroid inhibitors market include:

  • ChemGenix (India)
  • Ciba AG (Switzerland)
  • Crinetics Pharmaceuticals, Inc. (U.S.)
  • HRA Pharma (U.S.)
  • Merck KGaA (Germany)
  • Novartis AG (U.S.)
  • Recordati S.P.A (Italy)
  • Tocris Bioscience (U.K.)


SKU-
Why Choose Us


Frequently Asked Questions

The Adrenal Corticosteroid Inhibitors Market is projected to grow at a CAGR of 12.5% during the forecast period by 2030.
The future market value of the Adrenal Corticosteroid Inhibitors Market is expected to reach USD 5.77 billion by 2030.
The major players in the Adrenal Corticosteroid Inhibitors Market are ChemGenix (India), Ciba AG (Switzerland), Crinetics Pharmaceuticals, Inc. (U.S.), HRA Pharma (U.S.), Merck KGaA (Germany), Novartis AG (U.S.), Recordati S.P.A (Italy), and Tocris Bioscience (U.K.).
The countries covered in the Adrenal Corticosteroid Inhibitors Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, etc.